# Analyzing the potential targets and mechanisms of liver damage induced by acetyl tributyl citrate plasticizer using network toxicology, molecular docking and in vitro experiments

**Authors:** Dong-qun Guo, Yu-ming Fang, Zhen-dong Sun, Ya-fen Zeng, Gui-dan Wang, Jin-wei Liang

PMC · DOI: 10.3389/fphar.2025.1636576 · Frontiers in Pharmacology · 2025-07-16

## TL;DR

This study explores how the plasticizer acetyl tributyl citrate may cause liver damage by identifying key molecular targets and pathways involved in the process.

## Contribution

The study introduces a novel integration of network toxicology, molecular docking, and in vitro experiments to uncover mechanisms of ATBC-induced liver injury.

## Key findings

- 74 common targets were identified linking ATBC exposure and liver injury.
- ATBC showed specific binding affinity for TNF-α, suggesting its role in liver damage.
- In vitro experiments confirmed TNF-α's involvement in apoptosis during ATBC-induced liver injury.

## Abstract

Acetyl tributyl citrate (ATBC) may have adverse effects on liver health; however, the underlying mechanisms and pathophysiology remain unclear. The objective of this study was to elucidate the complex effects of ATBC on the liver and to determine the underlying molecular mechanisms by which environmental pollutants affect the disease process.

We used network toxicology and molecular docking techniques to analyze potential targets and mechanisms of liver injury caused by ATBC plasticizer. Potential targets associated with ATBC exposure and liver injury were identified by using ChEMBL, STITCH, GeneCards and OMIM databases. Enrichment analysis was performed using the DAVID database (https://david.ncifcrf.gov/) to identify biological pathways associated with these genes. Finally, transcription quantitative polymerase chain reaction, CCK-8 assay, Western blot, and immunofluorescence staining were used to assess the effect of candidate potential targets on liver injury.

A total of 74 common targets associated with ATBC and liver injury were obtained. Enrichment analysis emphasized the association between these plastocyanin-targeted genes and the apoptotic pathway, suggesting that plastocyanin has a broad impact on cell survival. Moreover, molecular docking analysis demonstrated that ATBC exhibited a specific binding affinity for TNF-α, thereby suggesting that TNF-α plays a pivotal role in the regulation of liver damage pathogenesis. In vitro experiments further validated the expression of this molecule with the apoptosis marker molecules BAX and Bcl2 in ATBC-induced liver injury.

The study suggests that TNF-α is involved in the process of ATBC-induced liver damage and may be related to cell apoptosis.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596]
- **Chemicals:** acetyl tributyl citrate (PubChem CID 6505), ATBC (PubChem CID 6505)

## Full-text entities

- **Genes:** BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737] {aka AIEFL, IMD57, RIP, RIP-1, RIP1}, BIRC3 (baculoviral IAP repeat containing 3) [NCBI Gene 330] {aka AIP1, API2, CIAP2, HAIP1, HIAP1, IAP-1}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, CLEC4D (C-type lectin domain family 4 member D) [NCBI Gene 338339] {aka CD368, CLEC-6, CLEC6, CLECSF8, Dectin-3, MCL}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, TRADD (TNFRSF1A associated via death domain) [NCBI Gene 8717] {aka Hs.89862}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551] {aka IKK-2, IKK-beta, IKK2, IKKB, IMD15, IMD15A}, MAP3K7 (mitogen-activated protein kinase kinase kinase 7) [NCBI Gene 6885] {aka CSCF, FMD2, MEKK7, TAK1, TGF1a}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, ROMO1 (reactive oxygen species modulator 1) [NCBI Gene 140823] {aka C20orf52, MTGM, MTGMP, bA353C18.2}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, TNFRSF1B (TNF receptor superfamily member 1B) [NCBI Gene 7133] {aka CD120b, TBPII, TNF-R-II, TNF-R75, TNFBR, TNFR1B}, PTPN11 (protein tyrosine phosphatase non-receptor type 11) [NCBI Gene 5781] {aka BPTP3, CFC, JMML, METCDS, NS1, PTP-1D}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, BIRC2 (baculoviral IAP repeat containing 2) [NCBI Gene 329] {aka API1, HIAP2, Hiap-2, IAP-2, MIHB, RNF48}, GSDMD (gasdermin D) [NCBI Gene 79792] {aka DF5L, DFNA5L, FKSG10, GSDMDC1}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, Bcl2l1 (BCL2-like 1) [NCBI Gene 12048] {aka Bcl(X)L, Bcl-XL, Bcl2l, BclX, bcl-x, bcl2-L-1}, BCL2A1 (BCL2 related protein A1) [NCBI Gene 597] {aka ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1}, TRAF2 (TNF receptor associated factor 2) [NCBI Gene 7186] {aka MGC:45012, RNF117, TRAP, TRAP3}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** atherosclerosis (MESH:D050197), necrotic prolapse (MESH:D011391), hepatocyte dysfunction (MESH:D006331), liver injury (MESH:D017093), endocrine-disrupting (MESH:D004700), inflammatory (MESH:D007249), cancer (MESH:D009369), prostate cancer (MESH:D011471), necrotic (MESH:D009336), ATBC (MESH:C562678), cytotoxicity (MESH:D064420), liver diseases (MESH:D008107), hepatic injury (MESH:D056486)
- **Chemicals:** Ib (MESH:D000069285), n-butanol (MESH:D020001), PVDF (MESH:C024865), ATBC (MESH:C014953), paraformaldehyde (MESH:C003043), DMSO (MESH:D004121), water (MESH:D014867), CCK-8 (MESH:D012844), PVC (MESH:D011143), SDS (MESH:D012967), ROS (MESH:D017382), DEHP (MESH:D004051), DAPI (MESH:C007293), lipid (MESH:D008055), citric acid (MESH:D019343), MCODE (-), CO2 (MESH:D002245), purine (MESH:C030985), Trizol (MESH:C411644), monobutyl phthalate (MESH:C028577), phthalate (MESH:C032279), CTC (MESH:C072046), BCA (MESH:C047117), MEHP (MESH:C016599), paracetamol (MESH:D000082)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** THLE-2 — Homo sapiens (Human), Transformed cell line (CVCL_3803)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12307183/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12307183/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12307183/full.md

---
Source: https://tomesphere.com/paper/PMC12307183